caa a22 4500 445824484 CHVBK 20180317145255.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1007/s00246-011-0010-0 doi (NATIONALLICENCE)springer-10.1007/s00246-011-0010-0 High-Dose Sotalol Is Safe and Effective in Neonates and Infants With Refractory Supraventricular Tachyarrhythmias [Elektronische Daten] [Jarrod Knudson, Bryan Cannon, Jeffrey Kim, Brady Moffett] Our objective was to assess the efficacy and safety of high-dose sotalol in neonates and infants with refractory supraventricular tachycardia (SVT). SVT in neonates and infants can be refractory to primary therapies; therefore, secondary agents, e.g., sotalol, are often required to obtain control of SVT. Age-factor nomogram dosing of sotalol is widely used; however, our institution uses greater doses based on body surface area (approximately 150-200mg/m2/d). A retrospective review of 78 inpatients receiving sotalol, after failing another antiarrthymic medication, at our institution from 2001 to 2008 was performed. Corrected QT intervals (QTc), 24-h Holter-monitoring results, and outpatient records were reviewed to assess safety and efficacy for patients ≤2years of age. Median patient age at the time of initiation of therapy was 24days (range 3-728). Forty-eight patients (62%) were neonates, and 36 (46%) had congenital heart disease. The median sotalol dosage was 152mg/m2/day (range 65-244). The SVT of 70 patients (90%) was controlled with sotalol. No patients experienced significant QTc prolongation or proarrhythmia. Mean duration of follow-up was 3.3±0.24years. High-dose sotalol allows for safe and rapid control of refractory tachyarrhythmias in this young age group. Springer Science+Business Media, LLC, 2011 Supraventricular tachycardia nationallicence Sotalol nationallicence Pediatric cardiology nationallicence Knudson Jarrod Department of Pediatric Cardiology, Baylor College of Medicine/Texas Children's Hospital, 6621 Fannin St., MC-19345-C, 77030, Houston, TX, USA aut Cannon Bryan Department of Pediatric Cardiology, Baylor College of Medicine/Texas Children's Hospital, 6621 Fannin St., MC-19345-C, 77030, Houston, TX, USA aut Kim Jeffrey Department of Pediatric Cardiology, Baylor College of Medicine/Texas Children's Hospital, 6621 Fannin St., MC-19345-C, 77030, Houston, TX, USA aut Moffett Brady Department of Pharmacy, Texas Children's Hospital, 77030, Houston, TX, USA aut Pediatric Cardiology Springer-Verlag 32/7(2011-10-01), 896-903 0172-0643 32:7<896 2011 32 246 https://doi.org/10.1007/s00246-011-0010-0 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00246-011-0010-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Knudson Jarrod Department of Pediatric Cardiology, Baylor College of Medicine/Texas Children's Hospital, 6621 Fannin St., MC-19345-C, 77030, Houston, TX, USA aut NATIONALLICENCE 700 1- Cannon Bryan Department of Pediatric Cardiology, Baylor College of Medicine/Texas Children's Hospital, 6621 Fannin St., MC-19345-C, 77030, Houston, TX, USA aut NATIONALLICENCE 700 1- Kim Jeffrey Department of Pediatric Cardiology, Baylor College of Medicine/Texas Children's Hospital, 6621 Fannin St., MC-19345-C, 77030, Houston, TX, USA aut NATIONALLICENCE 700 1- Moffett Brady Department of Pharmacy, Texas Children's Hospital, 77030, Houston, TX, USA aut NATIONALLICENCE 773 0- Pediatric Cardiology Springer-Verlag 32/7(2011-10-01), 896-903 0172-0643 32:7<896 2011 32 246 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer